TREACE MEDICAL CONCEPTS, Inc. 8-K Filing Summary

This 8-K filing reports the departure of Gaetano M. Guglielmino, Chief Commercial Officer, effective April 8, 2026. The company will not fill this role, and his responsibilities will be redistributed. Mr. Guglielmino will serve as an independent consultant until January 31, 2027, receiving a monthly fee, COBRA payments, a pro-rated bonus, rent assistance, and continued equity vesting. The filing also provides preliminary first-quarter 2026 financial outlook, with revenue expected between $47.0 million and $47.2 million, and cash, cash equivalents, and marketable securities totaling approximately $51.9 million as of March 31, 2026. Additionally, the company updates its full-year 2026 revenue guidance to $202 million - $212 million, citing continued case volume growth offset by product and price mix shifts.